Learn, Analyse & Invest
only with
only with
+91
Download Orca
Sandu Pharmaceuticals Ltd.
Sandu Pharmaceutical
Sandu Pharmaceuticals Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹35.20 Cr.
| EX-Date | Purpose |
|---|---|
| 10 06 2021 | Inter alia, to consider the following 1. To consider and take note of the said demise of Shri Bhaskar G Sandu (DIN:02816792), Chairman of our company. 2. To consider and recommend appointment of Statutory Auditor 3. Any other matter with the permission of Chairman. |
| 30 06 2021 | Audited Results |
| 14 08 2021 | Quarterly Results & Dividend |
| 13 11 2021 | Quarterly Results |
| 29 11 2021 | Inter alia, to consider and approve Appointment of Internal Auditor for Mumbai at its Corporate Office |
| 14 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 07 07 2022 | Inter alia, to consider and approve : 1. To Consider and Reappoint CMA Shekhar Joshi & Co, Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2022-23. 2. To Consider/Approve/Discuss on 03RD and Final Tranche, conversion of 8,50,326 nos of Equity Warrants Conversion into Equity Shares. 3. Any other matter. |
| 12 08 2022 | Quarterly Results & Dividend |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 30 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results & Final Dividend |
| 13 11 2023 | Quarterly Results |
| 14 02 2024 | Quarterly Results |
| 30 03 2024 | Inter alia, to consider and approve: - 1. To Consider and Appoint Chief Financial Officer of the Company. 2. Any other matter with the permission of Chairman. |
| 14 11 2024 | Quarterly Results |
| 13 02 2025 | Quarterly Results |
| 28 05 2025 | Final Dividend & Audited Results |
| 13 08 2025 | Quarterly Results |
| 14 10 2025 | Inter alia, to consider the following :- 1. To Approve Notice of Postal Ballot for reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter/ Promoter Group category to Public category pursuant to NOC received from Bombay Stock Exchange Limited dated 26 September 2025. 2. Any other matter with the permission of Chairman. |
| 12 11 2025 | Quarterly Results |
| 06 02 2026 | Quarterly Results |
| 05 05 2026 | Final Dividend & Audited Results |
| 11 07 2026 | Inter alia, to consider and approve:- 1. To place on record the demise of Shri Umesh B. Sandu(DIN:01132141), Managing Director of the Company, on 19th June, 2026, and to record the Board s appreciation for his invaluable contribution to the Company. 2. To consider and approve the appointment of a Managing Director of the Company pursuant to the demise of the erstwhile Managing Director, Late Shri Umesh B. Sandu, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals as may be required. 3. To consider and approve the reconstitution of the Committees of the Board. 4. To consider and approve the appointment of an Additional Director in the capacity of an Independent Director (Non-Executive) on the Board of the Company, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals, if any, as may be required. |
| 11 08 2026 | Quarterly Results |